Cargando…

Access to regulatory data from the European Medicines Agency: the times they are a-changing

Systematic reviewers are increasingly trying to obtain regulatory clinical study reports (CSRs) to correct for publication bias. For instance, our organization, the Institute for Quality and Efficiency in Health Care, routinely asks drug manufacturers to provide full CSRs of studies considered in he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wieseler, Beate, McGauran, Natalie, Kerekes, Michaela F, Kaiser, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495027/ https://www.ncbi.nlm.nih.gov/pubmed/23110993 http://dx.doi.org/10.1186/2046-4053-1-50

Ejemplares similares

Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information
por: McGauran, Natalie, et al.
Publicado: (2021)

Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews
por: Potthast, Regine, et al.
Publicado: (2014)

From publication bias to lost in information: why we need a central public portal for clinical trial data
por: Wieseler, Beate, et al.
Publicado: (2022)

Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data
por: Wieseler, Beate, et al.
Publicado: (2013)

Reporting bias in medical research - a narrative review
por: McGauran, Natalie, et al.
Publicado: (2010)

A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis
por: Janke, Kirsten, et al.
Publicado: (2022)

Negative pressure wound therapy: Potential publication bias caused by lack of access to unpublished study results data
por: Peinemann, Frank, et al.
Publicado: (2008)

Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
por: Köhler, Michael, et al.
Publicado: (2015)

A bacteriophage journey at the European Medicines Agency
por: Debarbieux, Laurent, et al.
Publicado: (2015)

Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
por: Ncube, Bakani Mark, et al.
Publicado: (2021)

Time to improve transparency at Health Canada’s Pest Management Regulatory Agency
por: Gagnon, Marc-André, et al.
Publicado: (2023)

Decisions by regulatory agencies: are they evidence-based?
por: Furberg, Curt D
Publicado: (2007)

Pharmacovigilance and the Italian Medicines Agency
por: Pimpinella, Giuseppe, et al.
Publicado: (2013)

Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance
por: Fazili, Masarret, et al.
Publicado: (2019)

Disagreement in primary study selection between systematic reviews on negative pressure wound therapy
por: Peinemann, Frank, et al.
Publicado: (2008)

The Role of Regulatory Sciences from the Perspective of the Cuban Medicines Regulatory Agency: The Impact of COVID-19 in Promoting Innovation, Cooperation and Scientific Thinking
por: Romeu, Belkis, et al.
Publicado: (2021)

Excellence in Family Paediatricians: the FIMP-MCRN (Medicines for Children Research Network) becomes a member of ENPR-EMA (European Network of Paediatric Research at the European Medicines Agency)
por: Napoleone, Ettore
Publicado: (2011)

Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs
por: Haag, Susanne, et al.
Publicado: (2021)

Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data
por: Janke, Kirsten, et al.
Publicado: (2020)

Revolving doors and conflicts of interest in health regulatory agencies in Brazil
por: Scheffer, Mário C, et al.
Publicado: (2020)

Commentary on the European Medicines Agency's extended mandate: Protecting public health in times of crisis and improving availability of medicines and medical devices
por: Abed, Inga, et al.
Publicado: (2022)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
por: Hines, Philip A., et al.
Publicado: (2020)

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022)

Medicines and Healthcare products Regulatory Agency’s “Consultation on proposals for legislative changes for clinical trials”: a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing
por: Law, Martin, et al.
Publicado: (2023)

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
por: Eyding, Dirk, et al.
Publicado: (2010)

Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Koyuncu, Oguzhan, et al.
Publicado: (2020)

Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA)
por: Shivji, Ragini, et al.
Publicado: (2022)

Guideline appraisal with AGREE II: online survey of the potential influence of AGREE II items on overall assessment of guideline quality and recommendation for use
por: Hoffmann-Eßer, Wiebke, et al.
Publicado: (2018)

Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Keyter, Andrea, et al.
Publicado: (2019)

Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency
por: Doshi, Peter, et al.
Publicado: (2016)

Real-world evidence (RWE): A challenge for regulatory agencies discussion of the RWE conference with the network of the european medicine agencies, patients, and experts
por: Maison, Patrick, et al.
Publicado: (2022)

Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010)

Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
por: Wiedermann, Christian J., et al.
Publicado: (2017)

A leap towards enforcing medicines prescribing by generic names in low- and middle-income countries (LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies
por: Merchant, Hamid A., et al.
Publicado: (2022)

Data processing at the European Space Agency
por: Mazza, C
Publicado: (1982)

Biomonitoring Studies Should Be Used by Regulatory Agencies to Assess Human Exposure Levels and Safety of Bisphenol A
por: Vandenberg, Laura N., et al.
Publicado: (2010)

Regulatory agencies have a role to play in maintaining consumer confidence in vaccine safety for pregnant women
por: Giles, Michelle L., et al.
Publicado: (2020)

Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA)
por: Portier, Christopher J, et al.
Publicado: (2016)

Aiming for agency and authenticity in assessment
por: Harrison, Christopher
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jae7cajn9p0v5fif45at6mbd6e